Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
Abstract Evinacumab, an angiopoietin‐like protein 3 (ANGPTL3) inhibitor, has been shown to significantly reduce low‐density lipoprotein cholesterol (LDL‐C) in patients with homozygous familial hypercholesterolemia (HoFH). This work characterized the population pharmacokinetics (PK)/pharmacodynamics...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Wiley
2021
|
| Subjects: | |
| Online Access: | https://doaj.org/article/7d13c590a1c64df5a16b0dbf274cfafe |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|